NASDAQ:CRBP - Corbus Pharmaceuticals Stock Price, Forecast & News

Corbus Pharmaceuticals trades on the NASDAQ under the ticker symbol "CRBP."

Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) announced its earnings results on Thursday, November, 7th. The biopharmaceutical company reported ($0.32) earnings per share for the quarter, beating analysts' consensus estimates of ($0.36) by $0.04. The biopharmaceutical company earned $2.59 million during the quarter, compared to analyst estimates of $1.73 million. Corbus Pharmaceuticals had a negative net margin of 175.16% and a negative return on equity of 169.38%. View Corbus Pharmaceuticals' Earnings History.

Corbus Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, March 10th 2020. View Earnings Estimates for Corbus Pharmaceuticals.

6 analysts have issued 1-year target prices for Corbus Pharmaceuticals' shares. Their forecasts range from $18.00 to $38.00. On average, they expect Corbus Pharmaceuticals' stock price to reach $26.50 in the next twelve months. This suggests a possible upside of 381.8% from the stock's current price. View Analyst Price Targets for Corbus Pharmaceuticals.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Corbus Pharmaceuticals in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Corbus Pharmaceuticals.

Media coverage about CRBP stock has trended somewhat negative recently, according to InfoTrie. The research firm identifies positive and negative press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Corbus Pharmaceuticals earned a daily sentiment score of -1.4 on InfoTrie's scale. They also assigned news coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View News Stories for Corbus Pharmaceuticals.

Some companies that are related to Corbus Pharmaceuticals include BELLUS Health (BLUSF), Endo International (ENDP), Madrigal Pharmaceuticals (MDGL), IGM Biosciences (IGMS), Y-mAbs Therapeutics (YMAB), Intra-Cellular Therapies (ITCI), Supernus Pharmaceuticals (SUPN), Rocket Pharmaceuticals (RCKT), Athenex (ATNX), Revance Therapeutics (RVNC), Phibro Animal Health (PAHC), Endonovo Therapeutics (ENDV), NextCure (NXTC), Portola Pharmaceuticals (PTLA) and Myovant Sciences (MYOV).

Based on aggregate information from My MarketBeat watchlists, some companies that other Corbus Pharmaceuticals investors own include Visa (V), HP (HPQ), Fortive (FTV), Lowe's Companies (LOW), Exelixis (EXEL), Viveve Medical (VIVE), Canopy Growth (CGC), Western Digital (WDC), Cronos Group (CRON) and Zynerba Pharmaceuticals (ZYNE).

Corbus Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Knoll Capital Management LP (7.80%), State Street Corp (1.73%), AdvisorShares Investments LLC (0.59%), Raymond James Financial Services Advisors Inc. (0.47%), Creative Planning (0.31%) and Bank of New York Mellon Corp (0.31%). Company insiders that own Corbus Pharmaceuticals stock include Barbara White, Craig Stuart Millian, David P Hochman, John Kenneth Jenkins, Robert Paul Discordia, Sean F Moran and Yuval Cohen. View Institutional Ownership Trends for Corbus Pharmaceuticals.

CRBP stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Exane Derivatives, Bank of America Corp DE, AE Wealth Management LLC, Raymond James Financial Services Advisors Inc., Ellington Management Group LLC, Prospera Financial Services Inc and Raymond James & Associates. View Insider Buying and Selling for Corbus Pharmaceuticals.

CRBP stock was purchased by a variety of institutional investors in the last quarter, including AdvisorShares Investments LLC, California Public Employees Retirement System, Knoll Capital Management LP, Virtus ETF Advisers LLC, UBS Group AG, State Street Corp, Omnia Family Wealth LLC and Charles Schwab Investment Management Inc.. Company insiders that have bought Corbus Pharmaceuticals stock in the last two years include Barbara White, Craig Stuart Millian, David P Hochman, John Kenneth Jenkins, Robert Paul Discordia, Sean F Moran and Yuval Cohen. View Insider Buying and Selling for Corbus Pharmaceuticals.

Shares of CRBP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of CRBP stock can currently be purchased for approximately $5.50.

Corbus Pharmaceuticals has a market capitalization of $355.69 million and generates $4.82 million in revenue each year. The biopharmaceutical company earns $-55,670,000.00 in net income (profit) each year or ($0.98) on an earnings per share basis. Corbus Pharmaceuticals employs 77 workers across the globe.View Additional Information About Corbus Pharmaceuticals.

The official website for Corbus Pharmaceuticals is http://www.corbuspharma.com/.

Corbus Pharmaceuticals' mailing address is 500 River Ridge Drive, Norwood MA, 02062. The biopharmaceutical company can be reached via phone at 617-963-0100 or via email at [email protected]